ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of medicines for patients with cancers. The company’s lead product candidate, firmonertinib, is an EGFR mutant-selective tyrosine kinase inhibitor being evaluated in Phase 3 trials for non-small cell lung cancer with uncommon EGFR mutations, including exon 20 insertions and PACC mutations. ArriVent also advances a pipeline of next-generation antibody drug conjugates, including ARR-217 for gastrointestinal cancers and ARR-002, a tetravalent MUC16/NaPi2b dual-target ADC. The company operates globally, excluding greater China, and has established strategic collaborations with partners such as Shanghai Allist Pharmaceuticals, Aarvik Therapeutics, Jiangsu Alphamab Biopharmaceuticals, and Lepu Biopharma to source and develop these therapeutics. Founded in 2021, ArriVent brings oncology assets to global markets that may otherwise remain limited to their regions of origin.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage arrivent.com
Sector Healthcare IR page ir.arrivent.com
Tags
oncology, non-small cell lung cancer, antibody drug conjugates, tyrosine kinase inhibitors, egfr mutations, gastrointestinal cancers, clinical-stage, biopharmaceuticals, firmonertinib, ARR-217, MRG007, ARR-002, Shanghai Allist Pharmaceuticals, Aarvik Therapeutics, Jiangsu Alphamab Biopharmaceuticals, Lepu Biopharma
Press page —

Metrics

Valuation  
Market cap $ 1.551B
Market cap (USD) $ 1.551B
P/E -8.63
PEG —
P/BV 3.94
P/S —
P/OCF -10.15
P/FCF -9.66
Dividend yield —
Turnover / mcap —
Returns  
ROE -58.9%
ROI -54.1%
ROIC -43.3%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Assets 333.169M 274.942M 163.098M 182.833M 43.039M
Net profit -166.308M -80.488M -69.333M -36.906M 0
Free cash flow -160.588M -70.212M -55.842M -43.631M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 20.12 26.64 — — —
Price performance 12m -0.24 — — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 317,000 176,000 14,000
Cash and deposits (USD) 163M 150M 74.3M 45.5M
Right-of-use assets (USD) — 291,000 154,000 13,000
Cash flow detail
Operating cash flow (USD) — -55.8M -70.2M -161M
Income taxes paid (cash effect) (USD) — — — 0.00
Share-based compensation (USD) — 895,000 3.21M 12.5M
Income detail
Research and development expense (USD) — 64.9M 79M 153M
Total comprehensive income (USD) — -69.3M -80.7M -166M
Comprehensive income to owners (USD) — -69.3M -80.7M -166M
Reported May 8, 2024 Mar 3, 2025 Mar 3, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

· Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC

· Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO

· Dosed first patient in U.S. Phase 1a/1b study of ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, with initial focus in ovarian and endometrial cancers

· Strengthened clinical leadership with announcement of Priti Patel, M.D., M.S., as Chief Medical Officer, bringing extensive oncology development experience

· Cash and investments of $393.2 million as of September 30, 2026 expected to fund operations to mid-2028

NEWTOWN SQUARE, PA, November 9, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent Company progress.

“Enrollment remains on track for our global Phase 3 ALPACCA trial in first line EGFR PACC mutant NSCLC patients.

October 25, 2026

PDF Version

  • 44.8% ORR at 6mg/kg dose in late-line CRC patients

  • ARR-217 was generally well-tolerated

  • ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program

NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.

"These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy," said Bing Yao, Ph.D., Chief Executive Officer of ArriVent. "We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study. As the first ADC from our pipeline to enter clinical development, ARR-217 represents an important milestone for our ADC pipeline, and we look forward to dose optimization data expected in 2027."

The ongoing multicenter, open-label Phase 1 study (NCT07066657) conducted in the US and China is evaluating the safety, tolerability, efficacy, and pharmacokinetics of ARR-217 in patients with unresectable, locally advanced, or metastatic solid tumors, with an initial clinical development focus in colorectal, pancreatic, and other gastrointestinal (GI) cancers. As of the August 5, 2026 data cutoff, 123 patients with heavily pretreated GI malignancies were treated across 6 dose levels ranging from 2 mg/kg to 8 mg/kg, including 113 patients with Colorectal Cancer (CRC).

Key Highlights for ARR-217 Phase 1 Study Include:

  • Strong Anti-tumor Activity with ARR-217 at Multiple Dose Levels

  • At 6 mg/kg Q3W dose, 44.8% (13/29) objective response rate (ORR) observed in pre-treated CRC patients, including 7 confirmed partial responses, 4 partial responses pending confirmation, and 2 unconfirmed partial responses

  • At 6 mg/kg Q3W dose, 93.1% (27/29) disease control rate (DCR) observed

  • At doses 4 mg/kg Q3W and higher, 34.2% (25/73) ORR observed in CRC patients, including 15 confirmed partial responses, 5 partial responses pending confirmation and 5 unconfirmed partial responses

  • At doses 4 mg/kg Q3W and higher, 91.8% DCR observed

  • Majority of the responding patients remained on study treatment as of the August 5, 2026 data cutoff

  • Generally, Well Tolerated Safety Profile

  • The most common treatment-related adverse events were Grade 1/2

  • Across all doses, 30.1% (37/123) patients experienced Grade 3 or higher treatment-related adverse events, including neutropenia (12.2%) and diarrhea (8.9%)

  • At 6.0 mg/kg Q3W dose, Grade 3 or higher TRAE was 20.4% (10/49) including 2.0% diarrhea (1/49)

  • No grade 5 TRAE or ILD observed

Dose Optimization and Next StepsARR-217 has advanced into Phase 1b dose optimization at doses of 5 and 6 mg/kg Q3W with further dose optimization data expected in 2027.

About ARR-217ARR-217 (also known as MRG007) is a potentially best-in-class cadherin-17 (CDH17)-targeted antibody-drug conjugate (ADC), utilizing a glycan-linked, exatecan-based payload. CDH17 is a membranous cell adhesion molecule frequently overexpressed in colorectal cancer and several other gastrointestinal cancers, with limited expression in normal intestinal tissue and pancreatic duct, making it an attractive target for ADC therapy. ArriVent obtained exclusive rights to develop and commercialize ARR-217 worldwide outside of Greater China under a collaboration agreement with Lepu Biopharma Co., Ltd. ARR-217 is the lead clinical candidate from ArriVent's growing ADC portfolio.

About ArriVent ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

Forward-Looking StatementsThis press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding, business strategy and plans; the activity safety and tolerability of ARR-217; the expected timing and future results of the ongoing clinical study of ARR-217, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

October 23, 2026

PDF Version

  • First-in-human data for ARR-217 selected as a late-breaking oral presentation

  • ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program

NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain, on October 23-27, 2026. ArriVent plans to host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data and ARR-217 program. To register for the event, click here.

Oral Presentation Details

Title: First-in-human study of MRG007 (ARR-217), a CDH17-directed exatecan ADC, in patients with locally advanced or metastatic solid tumors Abstract Number: LBA34 **Time and Date:**Sunday October 25, 2026 from 8:30 – 10:00 AM CEST **Session:**Rapid Oral Session

About ARR-217

ARR-217 (also known as MRG007) is a potentially best-in-class cadherin-17 (CDH17)-targeted antibody-drug conjugate (ADC), utilizing a glycan-linked, exatecan-based payload. CDH17 is a membranous cell adhesion molecule frequently overexpressed in colorectal cancer and several other gastrointestinal cancers, with limited expression in normal intestinal tissue and pancreatic duct, making it an attractive target for ADC therapy. ArriVent obtained exclusive rights to develop and commercialize ARR-217 worldwide outside of Greater China under a collaboration agreement with Lepu Biopharma Co., Ltd. ARR-217 is the lead clinical candidate from ArriVent's growing ADC portfolio.

About ArriVent ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, anti-tumor activity and safety of ARR-217, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

Prompts

ArriVent BioPharma, Inc. (ticker AVBP), listed in United States.

ETFs Holding ArriVent BioPharma, Inc.

ETF Weight in ETF Shares Market value As of
CANC 0.31% 21,729 $ 652.956K Aug 31, 2026
FSEG 0.13% 210 $ 7,295.40 Jun 30, 2026
VFMO 0.06% 37,104 $ 1.115M Aug 31, 2026
RESM 0.04% 39 $ 1,354.86 Jun 30, 2026
MSSM 0.01% 2,121 $ 63.736K Aug 31, 2026
DFAS 0.00% 123,324 $ 1.612M Nov 12, 2026
DCOR 0.00% 56,235 $ 734.991K Nov 12, 2026
DFAC 0.00% 60,788 $ 794.499K Nov 12, 2026
DFUS 0.00% 8,561 $ 111.892K Nov 12, 2026
DFAU 0.00% 5,030 $ 65.742K Nov 12, 2026